Comparing Dual Antiplatelet Therapy With Antiplatelet Plus Anticoagulation in Adults With Acute Coronary Syndrome and Coronary Artery Ectasia

What this Trial Is About

Coronary artery ectasia CAE is a condition where a coronary artery is abnormally dilated by at least 50% compared to nearby normal segments. This condition affects blood flow and raises the risk of blood clots, angina, heart attacks, and complications during coronary procedures. Researchers are studying the best antithrombotic treatment for patients with acute coronary syndrome ACS and CAE, as current treatment strategies remain uncertain despite the importance of managing clot risks effectively. The trial compares two antithrombotic approaches standard dual antiplatelet therapy using aspirin 100 mg plus clopidogrel 75 mg daily versus antiplatelet monotherapy with clopidogrel 75 mg combined with oral anticoagulation using rivaroxaban 15 mg daily. Participants are randomly assigned to one of these two treatments. This multicenter randomized clinical trial includes a translational research component to analyze blood samples for genetic and molecular markers that may influence CAE susceptibility and response to therapy. Participants will be followed for 12 months, during which researchers will monitor major adverse cardiovascular events and bleeding events using the BARC classification. Blood samples will be collected to study genetic factors associated with CAE and treatment response. The study aims to determine whether adding anticoagulation reduces cardiovascular events without significantly increasing bleeding risk. The trial is expected to provide important insights into managing this high-risk group over the course of the study.

Multicenter Trial of Antithrombotic Strategies in Acute Coronary Syndrome With Coronary Artery Ectasia